Bristol Myers Squibb Reblozyl gets expanded European nod for anemia in lower risk Myelodysplastic Syndromes Ruchika Sharma4 April 2024 2:13 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has expanded approval of Reblozyl (luspatercept) to include...
Bristol Myers Squibb gets EMA Committee positive opinion for Reblozyl for adults with Transfusion-Dependent Anemia due to Low-to Intermediate-Risk Myelodysplastic Syndromes Ruchika Sharma25 Feb 2024 3:30 PM ISTPrinceton: Bristol Myers Squibb has announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Bristol Myers Squibb gets USFDA nod for Reblozyl as first line treatment of Anemia in lower risk MDS Ruchika Sharma29 Aug 2023 11:09 AM ISTReblozyl, a first-in-class therapeutic option, promotes late-stage red blood cell maturation in animal models.
Bristol Myers Squibb gets USFDA priority review for expanded Reblozyl use Ruchika Sharma1 May 2023 5:31 PM ISTReblozyl, a first-in-class therapeutic option, promotes late-stage red blood cell maturation in animal models.
Bristol Myers Squibb Reblozyl gets European Commission nod for anemia due to Beta Thalassemia Ruchika Sharma5 March 2023 11:30 AM ISTReblozyl, a first-in-class therapeutic option, promotes late-stage red blood cell maturation in animal models.
Bristol Myers Squibb withdraws supplemental biologics license application for Reblozyl for Non-transfusion Dependent (NTD) Beta Thalassemia Ruchika Sharma5 Jun 2022 5:00 PM ISTReblozyl, a first-in-class therapeutic option, is currently approved in the United States, European Union and Canada to address transfusion-dependent...
